GlassScriptPhysician profile
James S Donald
NPI 1558339234
$4,840.73
in general payments reported to CMS, 2019-2025
30 companies · $632 in 2025
The $632 reported for 2025 was more than what 78% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $364 · 2020: $329 · 2021: $727 · 2022: $876 · 2023: $1,086 · 2024: $827 · 2025: $632.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,545.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,544.69 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $1,501.16 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Abbvie INC. | $1,182.67 | 2021-2024 | Vraylar, Qulipta, Ubrelvy |
| Astrazeneca Pharmaceuticals LP | $569.87 | 2019-2025 | Farxiga, Breztri, Airsupra |
| Bayer Healthcare Pharmaceuticals INC. | $361.52 | 2022-2025 | |
| Dexcom, INC. | $214.76 | 2021-2024 | Dexcom G6 Transmitter |
| Lilly USA, LLC | $154.95 | 2019-2025 | Mounjaro, Zepbound, Jardiance |
| Inspire Medical Systems, INC. | $122.09 | 2023 | Inspire |
| Janssen Pharmaceuticals, INC | $96.86 | 2019-2021 | |
| Astellas Pharma US INC | $78.01 | 2019 | |
| Pfizer INC. | $64.76 | 2020-2023 | |
| Novartis Pharmaceuticals Corporation | $56.71 | 2019-2023 | |
| Otsuka America Pharmaceutical, INC. | $56.01 | 2024-2025 | Rexulti |
| Corium, LLC | $38.44 | 2023-2025 | Azstarys |
| Allergan, INC. | $36.63 | 2019-2020 | |
| Paratek Pharmaceuticals, INC. | $36.31 | 2020-2021 |
Show all 30 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Axsome Therapeutics, INC. | $35.04 | 2023 | Auvelity |
| Exact Sciences Corporation | $29.93 | 2023 | Cologuard Collection Kit |
| Takeda Pharmaceuticals U.S.A., INC. | $26.53 | 2022-2023 | Trintellix |
| Biogen, INC. | $24.55 | 2021 | |
| Sanofi Pasteur INC. | $18.72 | 2025 | |
| Supernus Pharmaceuticals, INC. | $16.89 | 2022 | |
| Sanofi-Aventis U.S. LLC | $16.67 | 2021 | |
| Corcept Therapeutics | $14.08 | 2021 | |
| Biohaven Pharmaceutical Holding Company LTD. | $14.06 | 2022 | |
| Amgen INC. | $13.89 | 2022 | |
| Esperion Therapeutics, INC. | $13.62 | 2021 | |
| Merck Sharp & Dohme LLC | $13.58 | 2019 | |
| Avanir Pharmaceuticals, INC. | $13.48 | 2022 | |
| Eisai INC. | $12.86 | 2020 | |
| Galt Pharmaceuticals, LLC | $6.08 | 2023 | Orphengesic Forte |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw James Donald listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.